Chardan Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $9
Chardan Capital analyst Keay Nakae initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $9.
Coya Therapeutics Stock Down 3.79% Since IPO
Coya Therapeutics (NASDAQ:COYA) opened up its shares for public trading for the first time since it filed for…